Company intelligence / Profile preview

Inspyr Therapeutics

San Antonio, Texas, United Statesen.wikipedia.org ↗

Ownership: Private
Employees: ~1
Development stage: Phase 2

Overview

Lead candidate mipsagargin (G-202) has completed Phase 2 clinical trials for hepatocellular carcinoma (HCC) and glioblastoma. Mipsagargin received Orphan Drug Designation in HCC. Preclinical development is underway for proprietary adenosine receptor modulator compounds targeting various cancers and inflammatory diseases. Immune-oncology asset RT-AR001 is in preclinical or IND preparation phase and is designed to improve tumor infiltration and immune response.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeProdrugNanoparticleAdenosine receptor antagonistAdenosine receptor agonist
Industry: Biotech

Drug pipeline

2 assets

mipsagargin

1 more asset in the full pipeline.

Request access →

Partnerships

Lewis and Clark Pharmaceuticals (merger agreement, 2017)

Beyond the preview

Go deeper on Inspyr Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inspyr Therapeutics.

Explore the full profile